Abstract
Mutations in NS5B gene of Hepatitis C virus (HCV) have been reported in patients undergoing antiviral therapy. In the present study, we report emerging clade of HCV-3a in patients administered with IFN plus ribavirin therapy for 24 weeks and having low viral loads (<250 IU/mL). Mutations D/N244E, K304R, N/K307G, Q/T329V, and A338V were found associated with these emerging strains. This distinct HCV could be associated with the increased antiviral drug pressure.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Amino Acid Sequence
-
Antiviral Agents / therapeutic use*
-
Drug Resistance, Viral
-
Female
-
Genetic Variation*
-
Hepacivirus / classification
-
Hepacivirus / drug effects*
-
Hepacivirus / genetics*
-
Hepacivirus / isolation & purification
-
Hepatitis C / drug therapy*
-
Hepatitis C / virology*
-
Humans
-
Interferons / therapeutic use
-
Male
-
Middle Aged
-
Models, Molecular
-
Molecular Sequence Data
-
Mutation, Missense
-
Pakistan
-
Phylogeny
-
Ribavirin / therapeutic use
-
Sequence Alignment
-
Viral Nonstructural Proteins / chemistry
-
Viral Nonstructural Proteins / genetics
-
Young Adult
Substances
-
Antiviral Agents
-
Viral Nonstructural Proteins
-
Ribavirin
-
Interferons
-
NS-5 protein, hepatitis C virus